Literature DB >> 19100771

Allergen-specific immunotherapy.

Verena Niederberger1.   

Abstract

Allergy is a significant health problem in industrialized countries and its prevalence is continually on the increase: In 1906, when Clemens von Pirquet introduced the term "allergy" to describe overwhelming pathological reactions of the body caused by contact with antigens, less than 1% of the population were affected. Today, more than 25% of the inhabitants of industrialized countries suffer from allergic rhinitis, conjunctivitis, asthma, dermatitis or food allergies. Allergic symptoms can be alleviated using corticosteroids, antihistamines, cromones, decongestants, antimuscarinics or leukotrien antagonists. However, only immunotherapy is able to change the course of allergic disease and to lead to a long-term improvement which is sustained years after the discontinuation of this treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100771     DOI: 10.1016/j.imlet.2008.11.012

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

Review 1.  Treatment of allergic asthma: modulation of Th2 cells and their responses.

Authors:  Berislav Bosnjak; Barbara Stelzmueller; Klaus J Erb; Michelle M Epstein
Journal:  Respir Res       Date:  2011-08-25

2.  Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis.

Authors:  Jiarong Wang; Liansheng Qiu; Yimin Chen; Minyun Chen
Journal:  Open Med (Wars)       Date:  2021-05-21

3.  A naturally occurring hypoallergenic variant of vespid Antigen 5 from Polybia scutellaris venom as a candidate for allergen-specific immunotherapy.

Authors:  Sabrina E Vinzón; Cristina Marino-Buslje; Elena Rivera; Mirtha Biscoglio de Jiménez Bonino
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

4.  Regulating the Regulators: microRNA and Asthma.

Authors:  Jia-Wang Wang; Kunyu Li; Gary Hellermann; Richard F Lockey; Subhra Mohapatra; Shyam Mohapatra
Journal:  World Allergy Organ J       Date:  2011-06       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.